Tier 2 — strong

Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study

Bandala C, Carro-Rodríguez J, Cárdenas-Rodríguez N, Peña-Montero I, Gómez-López M, Hernández-Roldán AP, Huerta-Cruz JC, Muñoz-González F, Ignacio-Mejía I, Domínguez B, Lara-Padilla E
Nutrients 2024 16(14):2284

Bibliography

PubMed
PMID 39064727
PubMed Central
PMC11280467
DOI
10.3390/nu16142284
Funding
Reported funding sources: Instituto Politecnico Nacional; Consejo Nacional de Ciencia y Tecnología. Grant and funder-role details are in the publication.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample50 adults with obesity
InterventionBerberine versus Gymnema sylvestre; no placebo arm
Duration3 months
EndpointsLiver fat and liver enzymes; Body composition and weight; Metabolic biomarkers

What the study showed, in plain terms

The active-agent comparison reported different changes in body composition, metabolic markers and adipokine expression. It cannot establish either agent’s benefit relative to placebo.

Key findings

  • The active-agent comparison reported different changes in body composition, metabolic markers and adipokine expression. It cannot establish either agent’s benefit relative to placebo.

What this study can and cannot tell us

Small active-comparator study; between-treatment comparisons differ from within-arm changes.

Related papers in the corpus

Tier 2
Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial
Lei L et al. · JAMA network open · 2026
Tier 2
Effects of Berberine, White Mulberry Leaf Extract and Chromium Picolinate on Body Composition and Insulin Resistance in Adults with Obesity: A Randomized Controlled Trial
Xenos K et al. · Nutrients · 2026
Tier 2
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial
Koperska A et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2024
Tier 2
The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial
Nejati L et al. · Medical journal of the Islamic Republic of Iran · 2022
Tier 4
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
Chang X et al. · Journal of translational medicine · 2016

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology